Found: 24
Select item for more details and to access through your institution.
Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Opportunities for Earlier Diagnosis and Treatment of Cardiac Amyloidosis.
- Published in:
- Methodist DeBakey Cardiovascular Journal, 2022, v. 18, n. 5, p. 27, doi. 10.14797/mdcvj.1163
- By:
- Publication type:
- Article
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
- Published in:
- Cardiology & Therapy, 2022, v. 11, n. 3, p. 393, doi. 10.1007/s40119-022-00265-7
- By:
- Publication type:
- Article
Reference Ranges, Diagnostic and Prognostic Utility of Native T1 Mapping and Extracellular Volume for Cardiac Amyloidosis: A Meta‐Analysis.
- Published in:
- Journal of Magnetic Resonance Imaging, 2021, v. 53, n. 5, p. 1458, doi. 10.1002/jmri.27459
- By:
- Publication type:
- Article
Race, Sex, and Ejection Fraction-Based Differences in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Risk Prediction.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 20, p. 6150, doi. 10.3390/jcm13206150
- By:
- Publication type:
- Article
Changes in Left Ventricular Ejection Fraction and Clinical Trajectories of Transthyretin Cardiac Amyloidosis with Systolic Dysfunction.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 23, p. 7250, doi. 10.3390/jcm12237250
- By:
- Publication type:
- Article
Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality.
- Published in:
- Journal of Cardiovascular Electrophysiology, 2019, v. 30, n. 11, p. 2427, doi. 10.1111/jce.14180
- By:
- Publication type:
- Article
Primary prevention implantable cardioverter‐defibrillators in transthyretin cardiac amyloidosis.
- Published in:
- Pacing & Clinical Electrophysiology, 2020, v. 43, n. 11, p. 1401, doi. 10.1111/pace.14023
- By:
- Publication type:
- Article
Emerging Advances in the Management of Cardiac Amyloidosis.
- Published in:
- Current Cardiology Reports, 2015, v. 17, n. 11, p. 1, doi. 10.1007/s11886-015-0653-1
- By:
- Publication type:
- Article
Effect of long‐term tafamidis treatment on health‐related quality of life in patients with transthyretin amyloid cardiomyopathy.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 3, p. 612, doi. 10.1002/ejhf.3190
- By:
- Publication type:
- Article
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study.
- Published in:
- European Journal of Heart Failure, 2021, v. 23, n. 2, p. 277, doi. 10.1002/ejhf.2027
- By:
- Publication type:
- Article
ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable.
- Published in:
- 2021
- By:
- Publication type:
- journal article
A case series of cardiac amyloidosis patients supported by continuous-flow left ventricular assist device.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Mitral and tricuspid stenosis caused by light chain cardiac amyloid deposition.
- Published in:
- ESC Heart Failure, 2020, v. 7, n. 3, p. 1130, doi. 10.1002/ehf2.12668
- By:
- Publication type:
- Article
Minimally invasive biventricular mechanical circulatory support with Impella pumps as a bridge to heart transplantation: a first‐in‐the‐world case report.
- Published in:
- ESC Heart Failure, 2019, v. 6, n. 3, p. 552, doi. 10.1002/ehf2.12412
- By:
- Publication type:
- Article
Incidence and Prognostic Implications of Readmissions Caused by Thrombotic Events After a Heart Failure Hospitalization.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).
- Published in:
- Cardiovascular Drugs & Therapy, 2020, v. 34, n. 3, p. 357, doi. 10.1007/s10557-019-06919-4
- By:
- Publication type:
- Article
Supra-normal left ventricular ejection fraction in cardiac amyloidosis.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Management of the sensitized adult heart transplant candidate.
- Published in:
- Clinical Transplantation, 2010, v. 24, n. 6, p. 726, doi. 10.1111/j.1399-0012.2010.01259.x
- By:
- Publication type:
- Article
Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 7, p. 2723, doi. 10.1007/s12325-024-02891-0
- By:
- Publication type:
- Article
Prevalence of ATTR-CA and high-risk features to guide testing in patients referred for TAVR.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 13, p. 3910, doi. 10.1007/s00259-023-06374-2
- By:
- Publication type:
- Article